KB502

**KB502** is an investigational **DNA-encoded monoclonal antibody gene therapy** from **Krystal Biotech** designed for localized treatment of inflammatory skin disease. Available preclinical disclosures indicate that it is an **HSV-1-based topical vector** that expresses an **antibody targeting interleukin-4 receptor subunit alpha**, thereby aiming to block IL-4 and IL-13 signaling central to type 2 inflammation in **atopic dermatitis** and related skin disorders. Publicly available information suggests the program remained **preclinical** and was part of Krystal's broader vector-encoded antibody platform, with no evidence of commercial branding, approval, or late-stage clinical development.